going from mounjaro to retatrutide ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial 🚀 First Day on Retatrutide!

And in addition to causing your pancreas to release insulin, GLP-1 agonists also blocks a hormone that causes your liver to release sugar (glucagon)

Survodutide Dosing# In the Phase 2 obesity trial, survodutide was administered as once-weekly subcutaneous injections at doses of 0.6 mg, 2.4 mg, 3.6 mg, and 4.8 mg

Our team of compassionate, patient-centered experts is here to support you each step of the way as you work to achieve a balanced life in all areasphysical, emotional, and beyond

The titration schedule then steps up every 4 weeks so the body can adjust before higher doses are reached

2

For a plain explanation of why supplement style products are held to a different standard than approved drugs, see the United States Food and Drug Administration consumer guidance on dietary supplements, which explains why supplement style products are not tested for effectiveness before they are allowed to reach the market